UPDATE: Allergan (AGN) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to UPDATE: Allergan (AGN) Tops Q3 EPS by 9c
November 2, 2017 8:40 AM EDT
Morgan Stanley lowered its price target on Allergen (NYSE: AGN) to $200.00 (from $228.00) while maintaining a Equalweight rating following results.
Analyst David Risinger noted while guidance is encouraging they are lowering the price on lower Restasis earnings and Botox threats
...
More
November 2, 2017 8:39 AM EDT
RBC Capital lowered its price target on Allergen (NYSE: AGN) to $221.00 (from $250.00) while maintaining a Outperform rating following the company's 3Q earnings report.
Analyst Randall Stanicky still sees unlocked value and expect shareholder pressure to increase and add share support especially if that... More
November 1, 2017 10:34 AM EDT
Evercore ISI analyst Umer Raffat argues that Allergan (NYSE: AGN) stock should be up and thinks the call went well.
Raffat notes management was very clear about expectations into next year. They also provided clarity on milestone payments etc. over next few years.
From his perspective, the 3 most important things on the call... More
